Table 3:

Trials evaluating the effects of FXI inhibition in kidney failure.

Study	Population	Intervention	Number of participants	Primary outcome	Status
CS4, NCT02553889 (Phase 2)	Kidney failure treated with hemodialysis	Fesomersen (FXI antisense oligonucleotid) vs placebo	49	Safety and tolerability	Completed and published [72]
EMERALD, NCT03358030 (Phase 2)	Kidney failure treated with hemodialysis	IS 416858 (FXI antisense oligonucleotid) vs placebo	213	Number of participants with major bleeding or clinically relevant non major bleeding	Completed, results on clinicaltrials.gov, not yet published
RE-THINc ESRD, NCT04534114 (Phase 2b)	Kidney failure treated with hemodialysis	Fesomersen (FXI antisense oligonucelotid) vs placebo	307	Incidence of major bleeding or clinically relevant non major bleeding	Completed and published [66]
FXI Hemodialysis Study, NCT05027074 (Phase 2)	Kidney failure treated with hemodialysis via arteriovenous graft	MK-2060 (anti-FXI monoclonal antibody) vs placebo	489	Time to first arteriovenous graft thrombosis	Active, not yet recruiting
AB023, NCT03612856 (Phase 2)	Kidney failure treated with hemodialysis	AB023 (Xisomab, anti-FXI monoclonal antibody) vs placebo	27	Number of treatment-related adverse events	Completed and published [73]
CONVERT, NCT04523220 (Phase 2b)	Kidney failure treated with hemodialysis	Osocimab (anti-FXI monoclonal antibody) vs placebo	704	Cumulative incidence of risk of the first major bleeding or clinically relevant non major bleeding	Completed and published [65]